Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 3;8(7):1593806.
doi: 10.1080/2162402X.2019.1593806. eCollection 2019.

Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis

Qiaofen Fu  1   2 , Nan Chen  1 , Chunlei Ge  2 , Ruilei Li  2 , Zhen Li  2 , Baozhen Zeng  2 , Chunyan Li  2 , Ying Wang  2 , Yuanbo Xue  2 , Xin Song  2 , Heng Li  1 , Gaofeng Li  1
Affiliations
Review

Prognostic value of tumor-infiltrating lymphocytes in melanoma: a systematic review and meta-analysis

Qiaofen Fu et al. Oncoimmunology. .

Abstract

Tumor-infiltrating lymphocytes (TILs) are associated with prognosis in various tumors. However, it remains controversial whether the presence of TILs is related to an improved prognosis in melanoma. This meta-analysis confirmed the favorable prognostic role of the CD3+, CD4+, CD8+, FOXP3+, and CD20+ TILs in the overall survival of melanoma patients and found an association between the TILs present and improved overall survival. Additionally, subgroup analysis demonstrated that brisk TILs were obviously associated with OS, RFS and DSS/MSS. Thus, TILs may be a predictive biomarker in melanoma. This analysis will provide more insight into the study of TILs and predictive biomarker.

Keywords: Melanoma; prognostic biomarkers; systematic review; tumor-infiltrating lymphocytes (TILs).

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The flow diagram of studies selection and identification.
Figure 2.
Figure 2.
Forest plots of prognostic value of TILs present on overall survival in melanoma patients. * nail unit melanoma, ** non-nail unit acral melanoma.
Figure 3.
Figure 3.
Forest plots of prognostic value of different TIL grades on overall survival in melanoma patients.
Figure 4.
Figure 4.
Forest plots of prognostic value of different TIL grades on disease-free survival in melanoma patients. No data were available for the TILs present and only 1 study was met the moderate TILs.
Figure 5.
Figure 5.
Forest plots of prognostic value of TILs present (A) and different TIL grades (B) on progression-free survival in melanoma patients. Only 1 study was met the non-brisk TILs and no data were available for the moderate TILs.
Figure 6.
Figure 6.
Forest plots of prognostic value of TILs present (A) and different TIL grades (B) on disease-specific survival or melanoma-specific survival in melanoma patients. No data were available for the moderate TILs.
Figure 7.
Figure 7.
Funnel plot of of TILs present on overall survival.
See this image and copyright information in PMC

References

    1. Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, et al. Phase Ib/II study of pembrolizumab and pegylated-interferon alfa-2b in advanced melanoma. J Clin Oncol. 2018. Oct 25:JCO1800632. doi:10.1200/JCO.18.00632. - DOI - PMC - PubMed
    1. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480–1492. doi:10.1016/S1470-2045(18)30700-9. - DOI - PubMed
    1. Mohammadpour A, Derakhshan M, Darabi H, Hedayat P, Momeni M.. Melanoma: where we are and where we go. J Cell Physiol. 2019 Apr;234(4):3307–3320. doi:10.1002/jcp.27286. - DOI - PubMed
    1. Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res. 2015;21:3052–3060. doi:10.1158/1078-0432.CCR-14-3073. - DOI - PMC - PubMed
    1. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159–1166. - PubMed

Publication types